Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A study published in the journal Nature Genetics used genetic data from nearly a million people across Europe and North America to highlight some of the key ways in which type 2 diabetes develops, and to find several genes which could be attractive targets for the creation of new therapeutic drugs.

Hands of a woman taking a small blood sample in her finger

Image courtesy of Shutterstock

Together with colleagues from a global consortium of scientists, researchers from the Radcliffe Department of Medicine and the Wellcome Centre for Human Genetics at Oxford University analysed nearly 20 trillion data points to produce the most comprehensive catalogue so far of the places within the human genome where DNA sequence changes alter a person’s risk of developing Type 2 diabetes.

Diabetes occurs when the body’s ability to produce or respond to the hormone insulin is impaired, leading to elevated levels of glucose in the blood. Type 1 diabetes usually starts in childhood and is due to permanent loss of the beta cells in the pancreas that produce insulin. Type 2 diabetes typically develops later in life, and a person’s risk depends on the combination of genetic and lifestyle factors (such as diet and exercise, through their impact on a person’s weight).

Find out more (University of Oxford website)